Key facts
- Xellsmart’s last known valuation is $158.0M (Mar 2023).
- It has raised $156.1M; the latest was Later Stage VC ($72.4M) in Mar 2026.
- Notable investors include Suzhou Oriza Holdings Corporation, HSG (Hong Kong), Qiming Venture Partners, YuanBio Venture Capital, Frees Fund — 34 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 34 names
- ·Watchlist + deal alerts for Xellsmart
- ·The full record, as it builds
Funding rounds
No funding rounds for Xellsmart are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xellsmart
Developer of stem cell treatment solutions intended to improve major disease treatment and drug discovery. The company offers off-the-shelf candidates manufactured to clinical grade with integrated quality control, standardized processes spanning reprogramming and directed differentiation, and regulatory clearances for early-stage studies in Parkinson's disease, spinal cord injury, and amyotrophic lateral sclerosis, providing patients with clinical solutions.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Employees
- 100
- Website
- xellsmart.com/
- Ownership
- Privately Held (backing)
Xellsmart doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xellsmart shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xellsmart in its N-PORT filings yet. We sweep new filings monthly.